ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

HYDI Hydromer Inc (CE)

0.35
0.00 (0.00%)
30 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Hydromer Inc (CE) USOTC:HYDI OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.35 0.00 01:00:00

Hydromer Enters Into an Exclusive License Agreement With Ortopro AS for Implantable Orthopedic Devices

07/03/2013 3:47pm

Marketwired


Hydromer (CE) (USOTC:HYDI)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Hydromer (CE) Charts.

Hydromer, Inc. (OTC Pink: HYDI) announced that it entered into a royalty bearing Exclusive License Agreement with Ortopro AS (Ortopro) of Turkey.

Under the terms of this agreement, OrtoPro is licensed to use proprietary Hydromer® biofilm resistant coatings on various implantable orthopedic devices, such as bone screws. Test data has indicated that the licensed Hydromer coating formulation aids in reducing the infection risk of such implants. Ortopro has agreed to conduct additional biological and biocompatibility studies hopefully leading to regulatory approval in the Exclusive Territory of Turkey.

"We are tremendously proud and honored with our new relationship, which will help propel Hydromer's entry into the lucrative orthopedic implant market," commented Martin von Dyck, Executive Vice President of Hydromer, Inc., adding, "Hydromer and Ortopro have been working closely together in addressing the vexing problem of infections associated with orthopedic implants which are very difficult to resolve using conventional intravenous antibiotic therapy. In fact, often an infected implant must be removed or treated via another surgical procedure. It is our belief that the new Hydromer formula will mitigate this infection risk."

About Hydromer, Inc.: Hydromer, Inc. is a bio-technology-based company involved in the research and development, manufacture, contract coating and commercialization of specialized polymer and hydrogel products for medical device, animal health, cosmetic, personal care, and industrial uses. These technologies include Hydromer lubricious / anti-microbial / anti-thrombogenic / cell anti-mitosis / cell growth enhancing coatings for the medical marketplace.

For additional information please visit the following Web-site: www.hydromer.com

Hydromer® is a registered trademark of Hydromer, Inc.

Contact: Martin von Dyck Executive Vice President 35 Industrial Parkway Branchburg, NJ. USA Phone 908 722 5000 www.hydromer.com

1 Year Hydromer (CE) Chart

1 Year Hydromer (CE) Chart

1 Month Hydromer (CE) Chart

1 Month Hydromer (CE) Chart